Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received the first work order under its recently expanded Master Services Agreement with a current customer, one of the world’s leading pharmaceutical companies with a broad and active oncology pipeline.
The work order covers DiviTum® TKa testing services for a new oncology clinical study expected to initiate patient visits in September 2026. Testing will be performed through Biovica’s CLIA-certified laboratory in San Diego, California, and the work is expected to run over approximately two years.
The order value to Biovica is approximately SEK 1 million, including sample testing and related laboratory services.
“This first work order under the expanded agreement is an important step in converting our Pharma Services strategy into recurring project-based revenue. It demonstrates how our established laboratory services infrastructure can support pharmaceutical partners in oncology development and reinforces the commercial potential of DiviTum TKa as a functional biomarker in clinical drug development.” said Theis Kipling, CEO of Biovica.